[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Eero |
| 2. | Perekonnanimi | Vasar |
| 3. | Töökoht | Füsioloogia instituut, Tartu Ülikool |
| 4. | Ametikoht | professor, instituudi juhataja |
| 5. | Sünniaeg | 17.09.1954 (päev.kuu.aasta) |
| 6. | Haridus | 1962-1973 - Tartu 5. Keskkool, õpilane 1973-1979 - Tartu Riiklik Ülikool, Arstiteaduskonna raviosakonna üliõpilane 1979-1983 - Tartu Riiklik Ülikool, Füsioloogia kateeder, aspirant |
| 7. | Teenistuskäik | 1983-1991 - Tartu Riiklik Ülikool, ÜMPI Psühhofarmakoloogia labori juhataja, vanemteadur 1991 - Tartu Ülikool, Füsioloogia instituudi juhataja 1992 - Tartu Ülikool, Füsioloogia korraline professor |
| 8. | Teaduskraad | meditsiinidoktor |
| 9. | Teaduskraadi välja andnud asutus, aasta |
Tartu Ülikool, 1992 |
| 10. | Tunnustused | Eesti Vabariigi Punase risti III järgu orden, 2001 Eesti Vabariigi Teaduspreemia meditsiini alal, 2004 |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
TÜ Arstiteaduskonna teadusprodekaan Eesti Vabariigi esindaja ESF alalises meditsiinikomisjonis |
| 12. | Juhendamisel kaitstud väitekirjad |
Külli Kingo, PhD, 2005, juh. Eero Vasar; Sulev Kõks, Helgi Silm. THE INTERLEUKIN-10 FAMILY CYTOKINES GENE POLYMORPHISMS IN PLAQUE PSORIASIS. Tartu Sirli Raud, PhD, 2005, juh. Eero Vasar, Vallo Volke. CHOLECYSTOKININ2 RECEPTOR DEFICIENT MICE: CHANGES IN FUNCTION OF GABA-ERGIC SYSTEM. Tartu Alar Veraksitš, PhD, 2003, juh. Eero Vasar, Jaak Maaroos. CHARACTERIZATION OF BEHAVIOURAL AND BIOCHEMICAL PHENOTYPE OF CHOLECYSTOKININ 2 RECEPTOR-DEFICIENT MICE: CHANGES IN THE FUNCTION OF THE DOPAMINE– AND ENDOPIOIDERGIC SYSTEM. Tartu Sulev Kõks, PhD, 1999, juh. Eero Vasar; Mart Ustav. CHOLECYSTOKININ (CCK) - INDUCED ANXIETY IN RATS: INFLUENCE OF ENVIRONMENTAL STIMULI AND INVOLVEMENT OF ENDOPIOID MECHANISMS AND SEROTONIN. Tartu Vallo Volke, PhD, 1999, juh. Eero Vasar; Mart Ustav. PHARMACOLOGICAL AND BIOCHEMICAL STUDIES ON NITRIC OXIDE IN THE REGULATION OF BEHAVIOUR. Tartu Aavo Lang, PhD, 1995, juh. Eero Vasar. THE ROLE OF DOPAMINE, 5-HYDROXYTRYPTAMINE, SIGMA AND NMDA RECEPTORS IN THE ACTION OF ANTIPSYCHOTIC DRUGS. Tartu |
| 13. | Teadustöö põhisuunad | Ärevusseisundite neurobioloogilised mehhanismid. Transgeense tehnoloogia rakendamine vaimu- ja neurodegeneratiivsete haiguste molekulaarsete mehhanismide selgitamiseks. |
| 14. | Jooksvad grandid | 2003-2007 - Sihtfinantseerimsie teema "Uute molekulaarsete sihtmärkide selgitamine psühhiaatriliste haiguste diagnostikaks ja raviks" 2003-2005 - ETF grant nr. 5528 "Emotsionaalse käitumise regulatsioonis osalevate uute molekulaarsete sihtmärkide selgitamine ja transgeense tehnoloogia rakendamine nende funktsiooni uurimiseks" 2003-2005 - ETF grant nr. 5529 "Uued mudelid Parkinsoni tõve molekulaarsete mehhanismide selgitamiseks: alfa-sünukleiini ja parkini geenide suunatud mutatsioon hiirtel" 2003-2005 - Euroopa Liidu 5. Raamprogrammi projekt "Euroopa võrgustik Parkinsoni tõve uue ravistrateegia arendamiseks, kasutades lentiviirus vektor tehnoloogiat" |
| 15. | Teaduspublikatsioonid |
Areda T, Kõks S, Philips M-A, Vasar E, Karis A, Asser T Alterations in opioid system of the rat brain after cat odour exposure. Neuroscience Letters 2005, 377, 136-139. (online 22 December 2004). PMID: 15740852 [PubMed - indexed for MEDLINE] Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. Journal of Dermatological Science, 2005, 37, 111-113. (online 8 December 2004) PMID: 15659329 [PubMed - in process] Koido K, Kõks S, Nikopensius T, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. Int J Neuropsychopharmacol 2005 8:235-44. Epub 2004 Oct 11. PMID: 15473915 [PubMed - in process] Kõks S, Koido K, Nikopensius T, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E Analysis of SNP profiles in patients with major depressive disorder. Int. J. Neuropsychopharmacology, 2005 (accepted 14/03/2005, published online 01/06/2005). PMID: 15927089 [PubMed - as supplied by publisher] Kõks S, Vabrit K, Rätsep R, Kingo K, Silm H, Vasar E Possible relations between the polymorphisms of the cytokines IL 19, IL 20 and IL 24 and plaque-type psoriasis. Genes and Immunity, 2005 (accepted 18/03/2005) Online publication 12/05/2005. PPMID: 15889129 [PubMed - in process] Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, KoidoK, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J. Association study of 90 candidate genetic polymorphisms in panic disorder. Psychiatric Genetics 2005, 15, 17-24. PMID: 15722953 [PubMed - indexed for MEDLINE] Raud S, Innos J, Abramov U, Reimets A, Kõks S, Soosaar A, Matsui T, Vasar E Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology 2005 (in press 25 February 2005). Online publication 14 April 2005. PMID: 15830228 [PubMed - as supplied by publisher] Võikar V, Polus A, Vasar E, Rauvala H Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav 2005, 4, 240-252 (online 8 November 2004). PMID: 15924556 [PubMed - indexed for MEDLINE] Abramov U, Floren A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U. Regulation of feeding by galnon. Neuropeptides. 2004 Feb;38(1):55-61. PMID: 15003717 [PubMed - indexed for MEDLINE] Abramov U, Raud S, Koks S, Innos J, Kurrikoff K, Matsui T, Vasar E. Targeted mutation of CCK(2) receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behav Brain Res. 2004 Nov 5;155(1):1-11. PMID: 15325774 [PubMed - indexed for MEDLINE] Kingo K, Koks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004 Mar;5(2):117-21. PMID: 14712309 [PubMed - in process] Koks S, Luuk H, Nelovkov A, Areda T, Vasar E. A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain Behav. 2004 Apr;3(2):80-9. PMID: 15005716 [PubMed - indexed for MEDLINE] Kurrikoff K, Koks S, Matsui T, Bourin M, Arend A, Aunapuu M, Vasar E. Deletion of the CCK receptor gene reduces mechanical sensitivity and abolishes the development of hyperalgesia in mononeuropathic mice. Eur J Neurosci. 2004 Sep;20(6):1577-86. PMID: 15355324 [PubMed - indexed for MEDLINE] Kõks S, Kingo K, Rätsep R, Karelson M, Silm H, Vasar E Combined haplotype analysis of the interleukin-19 and interleukin-20 genes: relationship to plaque-type psoriasis. Genes Immunity 2004, 5, 662-667 (online 21 October 2004). PMID: 15496954 [PubMed - indexed for MEDLINE] Voikar V, Vasar E, Rauvala H. Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes Brain Behav. 2004 Feb;3(1):27-38. PMID: 14960013 [PubMed - indexed for MEDLINE] Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun. 2003 Sep;4(6):455-7. PMID: 12944983 [PubMed - indexed for MEDLINE] Koks S, Abramov U, Veraksits A, Bourin M, Matsui T, Vasar E. CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides. 2003 Feb;37(1):25-9. PMID: 12637032 [PubMed - indexed for MEDLINE] Nelovkov A, Philips MA, Koks S, Vasar E. Rats with low exploratory activity in the elevated plus-maze have the increased expression of limbic system-associated membrane protein gene in the periaqueductal grey. Neurosci Lett. 2003 Dec 11;352(3):179-82. PMID: 14625014 [PubMed - indexed for MEDLINE] Raud S, Runkorg K, Veraksits A, Reimets A, Nelovkov A, Abramov U, Matsui T, Bourin M, Volke V, Koks S, Vasar E. Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice. Psychopharmacology (Berl). 2003 Aug;168(4):417-25. Epub 2003 Apr 23. PMID: 12709779 [PubMed - indexed for MEDLINE] Roots K, Koks S, Kairane C, Salum T, Karelson E, Vasar E, Zilmer M. Na-pump kinetic properties are differently altered in the brain regions of the cholecystokinin2 receptor-deficient mice. Ann N Y Acad Sci. 2003 Apr;986:644-5. No abstract available. PMID: 12763910 [PubMed - indexed for MEDLINE] Runkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Koks S, Vasar E. Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res. 2003 Sep 15;144(1-2):125-35. PMID: 12946603 [PubMed - indexed for MEDLINE] Veraksits A, Runkorg K, Kurrikoff K, Raud S, Abramov U, Matsui T, Bourin M, Koks S, Vasar E. Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology (Berl). 2003 Mar;166(2):168-75. Epub 2003 Jan 24. PMID: 12545332 [PubMed - indexed for MEDLINE] Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res. 2003 Mar 18;140(1-2):141-7. PMID: 12644287 [PubMed - indexed for MEDLINE] Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol. 2003 Dec;54(4):653-60. PMID: 14726618 [PubMed - in process] Koks S, Planken A, Luuk H, Vasar E. Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat. Neurosci Lett. 2002 Apr 5;322(2):116-20. PMID: 11958857 [PubMed - indexed for MEDLINE] Koks S, Vasar E. Deramciclane (Egis). Curr Opin Investig Drugs. 2002 Feb;3(2):289-94. Review. PMID: 12020062 [PubMed - indexed for MEDLINE] Bentue-Ferrer D, Reymann JM, Tribut O, Allain H, Vasar E, Bourin M. Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol. 2001 Feb;11(1):41-50. PMID: 11226811 [PubMed - indexed for MEDLINE] Kask A, Vasar E, Heidmets LT, Allikmets L, Wikberg JE. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur J Pharmacol. 2001 Mar 2;414(2-3):215-24. PMID: 11239922 [PubMed - indexed for MEDLINE] Koks S, Beljajev S, Koovit I, Abramov U, Bourin M, Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl). 2001 Jan;153(3):365-72. PMID: 11271409 [PubMed - indexed for MEDLINE] Koks S, Volke V, Veraksits A, Runkorg K, Sillat T, Abramov U, Bourin M, Huotari M, Mannisto PT, Matsui T, Vasar E. Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl). 2001 Nov;158(2):198-204. PMID: 11702094 [PubMed - indexed for MEDLINE] Voikar V, Koks S, Vasar E, Rauvala H. Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav. 2001 Jan;72(1-2):271-81. PMID: 11240006 [PubMed - indexed for MEDLINE] Koks S, Mannisto PT, Bourin M, Shlik J, Vasar V, Vasar E. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci. 2000 Jan;25(1):33-42. PMID: 10721682 [PubMed - indexed for MEDLINE] Veraksits A, Bileviciute-Ljungar I, Maaroos J, Vasar E, Lundeberg T. Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in the rat hind paw. Neuropeptides. 2000 Apr;34(2):129-34. PMID: 10985930 [PubMed - indexed for MEDLINE] |
viimati muudetud: 04.08.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Eero |
| 2. | Surname | Vasar |
| 3. | Institution | Department of Physiology, University of Tartu |
| 4. | Position | professor, head of department |
| 5. | Date of birth | 17.09.1954 (day.month.year) |
| 6. | Education | 1962-1973 Tartu 5th Secondary School 1973-1975 Tartu State University, Medical Faculty, student 1979-1983 Tartu State University, Department of Physiology, Ph.D. student |
| 7. | Research and professional experience |
1983-1991 - Head, Laboratory of Psychopharmacology, Institute of General and Molecular Pathology, University of Tartu 1991 - Head, Department of Physiology, University of Tartu 1992 - Professor of Physiology, University of Tartu |
| 8. | Academic degree | Ph.D. in medicine |
| 9. | Dates and sites of earning the degrees |
University of Tartu, 1992 |
| 10. | Honours/awards | The third rank order of the Estonian Red Cross awarded by the President of Estonia, 2001 The scientific award of Estonia for Medicine, 2004 |
| 11. | Research-administrative experience |
Vice dean on research, Medical Faculty, University of Tartu Representative of Estonia, European Medical Research Council, European Science Foundation |
| 12. | Supervised dissertations |
Külli Kingo, PhD, 2005, superv. Eero Vasar; Sulev Kõks, Helgi Silm. THE INTERLEUKIN-10 FAMILY CYTOKINES GENE POLYMORPHISMS IN PLAQUE PSORIASIS. Tartu Sirli Raud, PhD, 2005, superv. Eero Vasar, Vallo Volke. CHOLECYSTOKININ2 RECEPTOR DEFICIENT MICE: CHANGES IN FUNCTION OF GABA-ERGIC SYSTEM. Tartu Alar Veraksitš, PhD, 2003, superv. Eero Vasar, Jaak Maaroos. CHARACTERIZATION OF BEHAVIOURAL AND BIOCHEMICAL PHENOTYPE OF CHOLECYSTOKININ 2 RECEPTOR-DEFICIENT MICE: CHANGES IN THE FUNCTION OF THE DOPAMINE– AND ENDOPIOIDERGIC SYSTEM. Tartu Sulev Kõks, PhD, 1999, superv. Eero Vasar; Mart Ustav. CHOLECYSTOKININ (CCK) - INDUCED ANXIETY IN RATS: INFLUENCE OF ENVIRONMENTAL STIMULI AND INVOLVEMENT OF ENDOPIOID MECHANISMS AND SEROTONIN. Tartu Vallo Volke, PhD, 1999, superv. Eero Vasar; Mart Ustav. PHARMACOLOGICAL AND BIOCHEMICAL STUDIES ON NITRIC OXIDE IN THE REGULATION OF BEHAVIOUR. Tartu Aavo Lang, PhD, 1995, superv. Eero Vasar. THE ROLE OF DOPAMINE, 5-HYDROXYTRYPTAMINE, SIGMA AND NMDA RECEPTORS IN THE ACTION OF ANTIPSYCHOTIC DRUGS. Tartu |
| 13. | Current research program | The neurochemical mechanisms of fear and anxiety The application of transgenic technology in the study of neurochemical basis of brain function |
| 14. | Current grant funding | 2003-2007 - Targeted Financing Project “New molecular targets for diagnosis and treatment of psychiatric disorders” 2003-2005 – Estonian Science Foundation Grant “New models for the study of molecular mechanisms of Parkinson’s disease: the targeted mutation of alpha-synuclein and parkin genes in mouse” 2003-2005 – Estonain Science Foundation Grant “The revealing of new molecular targets involved in the regulation of emotional behaviour and application of transgenic technology for study of their function” 2003-2005 European Union 5th Framework Grant “European network to develop new therapeutic strategies for Parkinson’s Disease using lentiviral vector technology” |
| 15. | List of most important publications |
Areda T, Kõks S, Philips M-A, Vasar E, Karis A, Asser T Alterations in opioid system of the rat brain after cat odour exposure. Neuroscience Letters 2005, 377, 136-139. (online 22 December 2004). PMID: 15740852 [PubMed - indexed for MEDLINE] Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. Journal of Dermatological Science, 2005, 37, 111-113. (online 8 December 2004) PMID: 15659329 [PubMed - in process] Koido K, Kõks S, Nikopensius T, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. Int J Neuropsychopharmacol 2005 8:235-44. Epub 2004 Oct 11. PMID: 15473915 [PubMed - in process] Kõks S, Koido K, Nikopensius T, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E Analysis of SNP profiles in patients with major depressive disorder. Int. J. Neuropsychopharmacology, 2005 (accepted 14/03/2005, published online 01/06/2005). PMID: 15927089 [PubMed - as supplied by publisher] Kõks S, Vabrit K, Rätsep R, Kingo K, Silm H, Vasar E Possible relations between the polymorphisms of the cytokines IL 19, IL 20 and IL 24 and plaque-type psoriasis. Genes and Immunity, 2005 (accepted 18/03/2005) Online publication 12/05/2005. PPMID: 15889129 [PubMed - in process] Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, KoidoK, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J. Association study of 90 candidate genetic polymorphisms in panic disorder. Psychiatric Genetics 2005, 15, 17-24. PMID: 15722953 [PubMed - indexed for MEDLINE] Raud S, Innos J, Abramov U, Reimets A, Kõks S, Soosaar A, Matsui T, Vasar E Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology 2005 (in press 25 February 2005). Online publication 14 April 2005. PMID: 15830228 [PubMed - as supplied by publisher] Võikar V, Polus A, Vasar E, Rauvala H Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav 2005, 4, 240-252 (online 8 November 2004). PMID: 15924556 [PubMed - indexed for MEDLINE] Abramov U, Floren A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U. Regulation of feeding by galnon. Neuropeptides. 2004 Feb;38(1):55-61. PMID: 15003717 [PubMed - indexed for MEDLINE] Abramov U, Raud S, Koks S, Innos J, Kurrikoff K, Matsui T, Vasar E. Targeted mutation of CCK(2) receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behav Brain Res. 2004 Nov 5;155(1):1-11. PMID: 15325774 [PubMed - indexed for MEDLINE] Kingo K, Koks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004 Mar;5(2):117-21. PMID: 14712309 [PubMed - in process] Koks S, Luuk H, Nelovkov A, Areda T, Vasar E. A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain Behav. 2004 Apr;3(2):80-9. PMID: 15005716 [PubMed - indexed for MEDLINE] Kurrikoff K, Koks S, Matsui T, Bourin M, Arend A, Aunapuu M, Vasar E. Deletion of the CCK receptor gene reduces mechanical sensitivity and abolishes the development of hyperalgesia in mononeuropathic mice. Eur J Neurosci. 2004 Sep;20(6):1577-86. PMID: 15355324 [PubMed - indexed for MEDLINE] Kõks S, Kingo K, Rätsep R, Karelson M, Silm H, Vasar E Combined haplotype analysis of the interleukin-19 and interleukin-20 genes: relationship to plaque-type psoriasis. Genes Immunity 2004, 5, 662-667 (online 21 October 2004). PMID: 15496954 [PubMed - indexed for MEDLINE] Voikar V, Vasar E, Rauvala H. Behavioral alterations induced by repeated testing in C57BL/6J and 129S2/Sv mice: implications for phenotyping screens. Genes Brain Behav. 2004 Feb;3(1):27-38. PMID: 14960013 [PubMed - indexed for MEDLINE] Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun. 2003 Sep;4(6):455-7. PMID: 12944983 [PubMed - indexed for MEDLINE] Koks S, Abramov U, Veraksits A, Bourin M, Matsui T, Vasar E. CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides. 2003 Feb;37(1):25-9. PMID: 12637032 [PubMed - indexed for MEDLINE] Nelovkov A, Philips MA, Koks S, Vasar E. Rats with low exploratory activity in the elevated plus-maze have the increased expression of limbic system-associated membrane protein gene in the periaqueductal grey. Neurosci Lett. 2003 Dec 11;352(3):179-82. PMID: 14625014 [PubMed - indexed for MEDLINE] Raud S, Runkorg K, Veraksits A, Reimets A, Nelovkov A, Abramov U, Matsui T, Bourin M, Volke V, Koks S, Vasar E. Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice. Psychopharmacology (Berl). 2003 Aug;168(4):417-25. Epub 2003 Apr 23. PMID: 12709779 [PubMed - indexed for MEDLINE] Roots K, Koks S, Kairane C, Salum T, Karelson E, Vasar E, Zilmer M. Na-pump kinetic properties are differently altered in the brain regions of the cholecystokinin2 receptor-deficient mice. Ann N Y Acad Sci. 2003 Apr;986:644-5. No abstract available. PMID: 12763910 [PubMed - indexed for MEDLINE] Runkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Koks S, Vasar E. Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res. 2003 Sep 15;144(1-2):125-35. PMID: 12946603 [PubMed - indexed for MEDLINE] Veraksits A, Runkorg K, Kurrikoff K, Raud S, Abramov U, Matsui T, Bourin M, Koks S, Vasar E. Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology (Berl). 2003 Mar;166(2):168-75. Epub 2003 Jan 24. PMID: 12545332 [PubMed - indexed for MEDLINE] Volke V, Wegener G, Bourin M, Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res. 2003 Mar 18;140(1-2):141-7. PMID: 12644287 [PubMed - indexed for MEDLINE] Volke V, Wegener G, Vasar E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J Physiol Pharmacol. 2003 Dec;54(4):653-60. PMID: 14726618 [PubMed - in process] Koks S, Planken A, Luuk H, Vasar E. Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat. Neurosci Lett. 2002 Apr 5;322(2):116-20. PMID: 11958857 [PubMed - indexed for MEDLINE] Koks S, Vasar E. Deramciclane (Egis). Curr Opin Investig Drugs. 2002 Feb;3(2):289-94. Review. PMID: 12020062 [PubMed - indexed for MEDLINE] Bentue-Ferrer D, Reymann JM, Tribut O, Allain H, Vasar E, Bourin M. Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. Eur Neuropsychopharmacol. 2001 Feb;11(1):41-50. PMID: 11226811 [PubMed - indexed for MEDLINE] Kask A, Vasar E, Heidmets LT, Allikmets L, Wikberg JE. Neuropeptide Y Y(5) receptor antagonist CGP71683A: the effects on food intake and anxiety-related behavior in the rat. Eur J Pharmacol. 2001 Mar 2;414(2-3):215-24. PMID: 11239922 [PubMed - indexed for MEDLINE] Koks S, Beljajev S, Koovit I, Abramov U, Bourin M, Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl). 2001 Jan;153(3):365-72. PMID: 11271409 [PubMed - indexed for MEDLINE] Koks S, Volke V, Veraksits A, Runkorg K, Sillat T, Abramov U, Bourin M, Huotari M, Mannisto PT, Matsui T, Vasar E. Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl). 2001 Nov;158(2):198-204. PMID: 11702094 [PubMed - indexed for MEDLINE] Voikar V, Koks S, Vasar E, Rauvala H. Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav. 2001 Jan;72(1-2):271-81. PMID: 11240006 [PubMed - indexed for MEDLINE] Koks S, Mannisto PT, Bourin M, Shlik J, Vasar V, Vasar E. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatry Neurosci. 2000 Jan;25(1):33-42. PMID: 10721682 [PubMed - indexed for MEDLINE] Veraksits A, Bileviciute-Ljungar I, Maaroos J, Vasar E, Lundeberg T. Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in the rat hind paw. Neuropeptides. 2000 Apr;34(2):129-34. PMID: 10985930 [PubMed - indexed for MEDLINE] |
last updated: 04.08.2005
[ sulge aken ]